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Abstract: A vancomycin-intermediate Staphylococcus aureus (VISA) outbreak occurred in an intensive
care unit (ICU) in South Korea. We aimed to investigate the condition that led to the VISA outbreak
and seek measures to prevent further spread of the multidrug-resistant organism. A total of three
VISA isolates were obtained from two patients and a health care worker (HCW) in a newly built
450-bed secondary hospital. Extensive screening of close contacts for VISA in terms of space sharing
and physical contact, irrespective of contact time, was performed. Furthermore, multilocus sequence
type, staphylococcal cassette chromosome mec type, and spa type profiles were determined for all
VISA isolates. The relationship between vancomycin use and the minimum inhibitory concentration
(MIC) of S. aureus was also investigated. Molecular typing showed that the strains of the three VISA
isolates were identical, indicating horizontal hospital transmission. We assumed that VISA colonised
in the HCW could have transmitted to the two patients, which resulted in one infection and one
colonisation. The affected HCW was excused from work and was decolonised with mupirocin. Five
weeks after the interventions, no additional VISA isolates were identified. No relationship between
vancomycin use and MIC of S. aureus was identified. Extensive screening of contacts in addition to
decolonisation is crucial in preventing the further spread of VISA.
Keywords: vancomycin-intermediate Staphylococcus aureus; healthcare-associated infection; outbreak;
infection control; antimicrobial resistance
1. Introduction
Antimicrobial resistance (AMR) is a global concern threatening public health. In-
fections caused by bacteria with AMR increase the risk of death and the costs of health
care [1]. Methicillin-resistant Staphylococcus aureus (MRSA) is one of the major pathogens
with AMR that infects humans. Vancomycin has been used as the first-choice drug to treat
MRSA infection for decades. With the spread of MRSA infection worldwide, the empirical
use of vancomycin has increased [2]. Consequently, the selective pressure of vancomycin
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has led to the emergence of S. aureus with reduced susceptibility to vancomycin, such as
vancomycin-intermediate S. aureus (VISA) [3,4]. Following the first report of VISA from
Japan in 1997, additional cases have been reported from several countries over the past
two decades [5]. In South Korea, VISA was first isolated in 1998. Since it was designated as
a notifiable bacterium with AMR in 2000, the number of reports has increased. Domestic
cases of VISA have been sporadically reported across the country, but there have not been
any previous reports of a VISA outbreak [6,7]. As a result, evidence regarding how to
respond to VISA outbreaks is lacking [8,9]. Previous reports on VISA outbreaks suggested
that considerable time and effort were required to control them due to the challenges in the
early detection of the event and the high transmissibility of the pathogen.
Here, we describe the first outbreak of VISA that occurred in the intensive care unit
(ICU) of a newly built secondary care hospital in South Korea. Compared with previous
reports, this outbreak was rapidly controlled due to the rapid detection of colonising
bacterial strains and prompt response. Based on the lessons learned from this experience,
we aimed to investigate the conditions that lead to VISA outbreaks and to identify efficient
measures to prevent further spread of the multidrug-resistant organism.
2. Results
2.1. Clinical Characteristics of Subjects with Vancomycin-Intermediate Staphylococcus
aureus Isolates
During the study period, three VISA isolates were obtained from two patients and
one health care worker (Figure 1). The clinical characteristics of the three individuals with
VISA infection are described in Table 1. VISA was isolated from the sputum of a 66 year
old man (Patient 1) with pneumonia. A subsequent nasal surveillance culture revealed
that he was not an MRSA coloniser. Glycopeptides had previously been administered to
the patient for 9 days for pneumonia treatment before the emergence of VISA. Although
the vancomycin was switched with linezolid after the isolation of the VISA strain from his
sputum, he died. Another VISA isolate was obtained from Patient 2, a 46 year old man; this
was considered a transmitted case of colonisation without the signs of pulmonary infection.
He died due to an intracerebral haemorrhage (his admission diagnosis). Among health
care workers who were subjects of the contact investigation, the nasal cavity swab culture
from a nurse (Nurse A) was positive for VISA. She was the nurse in charge of Patient 2,
and participated in taking care of Patient 1. To eliminate the carriage of VISA, intranasal
mupirocin was applied twice a day for 5 days. Repeat follow-up specimens were obtained
over 3 weeks after initiating treatment, and all culture results were negative for VISA.
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Table 1. Clinical and microbiological features of the vancomycin-intermediate Staphylococcus aureus cases identified during
the outbreak.
Variable Patient 1 Patient 2 Nurse A
Clinical characteristics
Age (years) 66 46 34
Sex Male Male Female
Specimen Sputum Sputum Nasal cavity
Diagnosis on ICU admission Acute myeloid leukaemia, pneumonia Intracerebral haemorrhage, hypertension None
Risk factors associated with VISA Previous vancomycin use, indwellingmedical devices Indwelling medical devices None
Case definition Presence of infection Colonisation Colonisation
Outcome Died Died Decolonisation
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Table 1. Cont.
Variable Patient 1 Patient 2 Nurse A
Antimicrobial resistance profiles of VISA
Ciprofloxacin ≥8 ≥8 ≥8
Clindamycin ≥8 ≥8 ≥8
Erythromycin ≥8 ≥8 ≥8
Telithromycin ≥4 ≥4 ≥4
Gentamicin ≥16 ≥16 ≥16
Mupirocin 4 4 4
Oxacillin ≥4 ≥4 ≥4
Penicillin G ≥0.5 ≥0.5 ≥0.5
Quinupristin/dalfopristin 0.5 0.5 ≤0.25
Rifampicin ≤0.5 ≤0.5 ≤0.5
Trimethoprim/Sulfamethoxazole ≤10 ≤10 ≤10
Tetracycline ≥16 ≥16 ≥16
Tigecycline 1 0.5 0.5
Nitrofurantoin 32 32 ≤16
Teicoplanin 16 8 8
Vancomycin 4 4 4
Linezolid 4 4 2
Molecular features of VISA
MLST ST5 ST5 ST5
SCCmec type II II II
spa type t2460 t2460 t2460
ICU, intensive care unit; MLST, multilocus sequence typing; SCCmec, Staphylococcal cassette chromosome mec; VISA, vancomycin-
intermediate Staphylococcus aureus.
2.2. Microbiological Characteristics of Vancomycin-Intermediate Staphylococcus aureus
The bacteriological characteristics were evaluated to determine the antimicrobial
resistance profiles and molecular types of the VISA isolates (Table 1). Antimicrobial suscep-
tibility tests of VISA were performed for 17 antimicrobial agents. The minimum inhibitory
concentration (MIC) of vancomycin was 4 µg/mL in all isolates. Two of the isolates were
susceptible to teicoplanin, and the other had intermediate resistance to teicoplanin (MIC of
16 µg/mL). All isolates were susceptible to linezolid, quinupristin/dalfopristin, rifampicin,
trimethoprim/sulfamethoxazole, and nitrofurantoin, and had high levels of resistance to
ciprofloxacin, clindamycin, erythromycin, gentamicin, and oxacillin.
The multilocus sequence typing (MLST) patterns of the three isolates were identical
(sequence type (ST) 5). Similarly, all three isolates were of the identical staphylococcal
cassette chromosome mec (SCCmec) type (type II) and spa type (t2460).
2.3. Amount of Vancomycin Used and Changes in the Vancomycin Minimum Inhibitory
Concentration for Staphylococcus aureus
The trends in vancomycin consumption and vancomycin MIC for S. aureus isolates
are shown in Figure 2. The amount of vancomycin used increased from 49.15 defined daily
dose (DDD) per 1000 patient days (PDs) in March 2020 to 78.52 DDD per 1000 PDs in June
2020. However, there was a marked decrease in vancomycin use in July and August 2020,
to 45.60 and 36.87 DDD per 1000 PDs, respectively. A total of 160 S. aureus isolates were
obtained from March 2020 to August 2020. The percentage of isolates with a vancomycin
MIC of 1 µg/mL continuously increased from 65% to 96% and then decreased to 55%.
The opposite trend was observed in the distribution of isolates with a vancomycin MIC of
≤0.5 µg/mL during the same period. Isolates with a vancomycin MIC of 2 µg/mL began
to appear in July 2020.
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3. Discussion
This is the first study describing a VISA outbreak in an ICU in South Korea. We
presume that the nurse colonised with VISA was responsible for VISA transmission to
the two ICU patients. One patient developed a VISA infection, and the other patient was
colonised by VISA. Prompt contact investigation and mupirocin decolonisation resulted
in the early termination of the outbreak. About 5 weeks after the first detection of VISA,
the outbreak ended and no fur her VISA isolates were re o ted during the 3 months
of follow-up.
Previous studies have shown that most VISA strains emerged in patients with MRSA
undergoing prolonged therapy with vancomycin [10,11]. However, the increased incidence
of VISA is not necessarily attributable solely to increased vancomycin use. One epidemi-
ological study found that nearly half of the VISA isolates wer from patients without a
history of MRSA infection or vancomycin use [6,12]. Consistent with pr vious reports,
our study found that the amount of vancomycin used had no direct effect on the MIC of
S. aureus isolates in the hospital. All isolates in our study were the same strains, which
indicated horizontal transmission within the hospital. Horizontal transmission can be the
cause of VISA emergence. As a newly built institution is not likely to have a reservoir for
multidrug-resistant organisms, it is reasonable to ass me that the VISA was introduced
from an outside source through a person instead of acquired from the environment. This
led us to conclude that the best prophylactic measure to prevent an outbreak of VISA is
prompt screening with a nasal swab of the ICU patients and staff working in the ICU when
VISA is first detected. Monitoring the usage of vancomycin or investigating the MRSA
prevalence may not be a efficient means of preventing VISA emergence.
Previous studies of VISA outbreaks have highlighted the importance of isolation a d
strict contact precaution to terminate large-scale outbreaks [8,9]. One study described a
VISA outbreak that affected 21 inpatients in a French hospital [8]. Another study, performed
in a hospital in Japan, described a VISA outbreak in which 19 VISA isolates were obtained
from 17 inpatients [9]. Although the staff involved in the control of the outbreak in the two
hospitals impl mented a variety of infection control measures, partial closure of the ICUs
were unavoidable, and it took several months to eradicate the outbreaks. Compared with
our study, the first case of VISA was recognised relatively late, which may have contributed
to the long time taken to end the outbreak. For early detection of VISA cases, extensive
investigation screening for colonisers on detection of the first case is imperative not only
in contacts who have spent extended time with a case, but also in those who have shared
fomites with a case.
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The molecular epidemiology and resistance profiles of VISA in South were described
in a previous study [13]. The most prevalent molecular type was ST5-SCCmec type II-t2460,
followed by ST72-SCCmec type IV-t324. A recent study, which used national data of VISA
strains isolated between 2014 and 2016, reported similar results [6]. Concordant with the
national molecular epidemiology, all VISA isolates in our study were of the ST5-SCCmec
type II-t2460 genotype, which may have originated in a healthcare setting [14]. As for
the resistance profiles of VISA, all the VISA strains were multidrug resistant in our study.
However, consistent with previous studies [6,13], we found that all three VISA isolates were
susceptible to linezolid. This finding indicates that linezolid can be used as a therapeutic
option for VISA infections.
For asymptomatic individuals colonised with S. aureus, nasal decolonisation with
mupirocin is a potential strategy that may be used to prevent infection [15,16]. Intranasal
mupirocin can lead to a reduction in the nasal carriage of S. aureus. However, limited
information is available regarding the effectiveness of mupirocin for VISA decolonisation.
In our study, a healthcare worker colonised with VISA (mupirocin MIC 4 µg/mL) was
treated with mupirocin; subsequently, three cultures for VISA were negative over a 3 week
period. Furthermore, no additional VISA isolates were identified in the 3 months after her
return to the hospital. The effectiveness of intranasal mupirocin for VISA decolonisation
needs to be determined by means of further studies.
We demonstrated an association between the amount of vancomycin consumption and
the vancomycin MIC of S. aureus. Vancomycin MIC creep was observed among S. aureus
isolates in our hospital during the period of increased vancomycin use. Similar findings
have been reported in other studies [17,18]. However, our results should be interpreted
with caution. The observation period was too short to conclude that there was a relationship
between the level of vancomycin consumption and the vancomycin MIC of S. aureus. In
addition, the VISA outbreak strain emerged in the presence of decreasing vancomycin
consumption. Further observation over a longer time period is necessary to evaluate the
relationship between the amount of vancomycin use and the VISA isolation rate.
There were some limitations in this study. First, both patients died early, obscuring
the actual effect of enhanced infection control measures. Second, the small number of
cases prevented us from further investigating the mode of VISA transmission. Third, we
were unable to perform genetic analysis for specific genes that could have determined the
mechanism involved in antimicrobial resistance. However, our study has significance in
that it showed the importance of early detection of VISA in preventing a large outbreak.
The isolation of VISA strains has been continuously reported in South Korea since
1998. This report describes the first VISA outbreak in South Korea, which occurred through
horizontal transmission in the ICU of a newly built secondary care hospital. Early detection
of the outbreak through an extensive search for colonisers through nasal swab screening fol-
lowed by the implementation of effective infection control measures (including mupirocin
decolonisation) resulted in the successful control of the outbreak. Further studies on the
effectiveness of mupirocin application in preventing the spread of VISA are required. Clini-
cians should suspect a VISA outbreak if multiple cases of VISA infection are identified in a
healthcare setting within a short period of time.
4. Materials and Methods
4.1. Setting
This study was conducted at Yong-in Severance Hospital, South Korea, which was
opened in March 2020. The hospital has 450 beds, including an ICU with 19 beds that was
in operation at the time of outbreak. The ICU consists of 15 large private rooms and four
open beds separated by curtains. Critically ill patients were admitted to the ICU because of
their medical or surgical conditions. There were 3 critical-care specialists, 24 nurses, and
5 nurse assistants working in the ICU.
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4.2. Outbreak and Intervention
The first patient (Patient 1) identified with VISA was admitted to the hospital on
12 August 2020 for acute myeloid leukaemia and was referred to the ICU on day 5 due
to pneumonia requiring mechanical ventilation. A strain of VISA was detected from the
patient’s sputum 9 days after ICU admission. On the following day, an isolate of VISA
was reported from the sputum of another patient (Patient 2) who had been in the ICU
for 17 days and was on mechanical ventilation. Transmission was suspected, as the two
patients were staying in adjacent private rooms in the ICU (Figure 3). Infection control
interventions were implemented immediately after detection of the second VISA isolate.
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obtained from a patient in room 11, and the second isolate was obtained from a patient in room 12.
A contact investigation was performed soon after report of the second case. Contacts
were classified into three categories based on the level of interaction with the VISA patients
using the Real-Time Location System tracing system: extensive, moderate, and minimal [19].
We conducted the investigation in a step-wise manner. Nasal swab specimens were
collected sequentially, starting with those who had had extensive contact with the patients
from whom VISA had been isolated. If positive results were identified among these contacts,
we extended the scope of the investigation to the next category. Among 24 contacts, one
member of the nursing staff was classified as having extensive contact with Patient 2 but
minimal contact with Patient 1, and was fou d to be p sitive for VISA on nasal swab
culture. Therefore, specimen collection was extended to 23 persons who had had m derate
interactions with the patients of interest. All samples collected from 23 persons tested
negative for VISA. In hindsight, we concluded that the member of the nursing staff with
the positive culture was probably the source case of the VISA outbreak. However, no
further isolates of VISA were cultured among patients who the nurse had taken care of
or among her co-workers. Environmental samples were also collected from surfaces and
equipment in the VISA patients’ rooms as well as from work spaces in the ICU (bed fence,
infusion pump, medication carts, dressing trolleys, telephones, monitor panels, automatic
door buttons, computer keyboards, and electrocardiography machines).
The nurse with a positive VISA result was excused from patient-care activities. Contact
precautions were implemented for the patients from whom VISA was isolated. All health
care workers were required to wear gowns and gloves before contacting these patients.
Hand hygiene was reinforced and monitored by an infection control team. The ICU staff
were provided education on infection control policies for VISA.
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4.3. Laboratory Tests for Staphylococcus aureus
The MIC of an antimicrobial agent was determined in the hospital using a VITEK-2
analyser (bioMérieux, Hazelwood, MO, USA). Antimicrobial susceptibility testing for
S. aureus was performed for penicillin, oxacillin, gentamicin, ciprofloxacin, erythromycin,
telithromycin, clindamycin, linezolid, teicoplanin, vancomycin, tetracycline, tigecycline, ni-
trofurantoin, mupirocin, rifampicin, quinupristin/dalfopristin, and trimethoprim/
sulfamethoxazole. The susceptibility results were interpreted according to the Clinical and
Laboratory Standards Institute guidelines [20]. All S. aureus strains with a vancomycin
MIC of ≥4 µg/mL were sent to the Institute of Health and Environment for confirmatory
testing using broth microdilution. S. aureus strains with a vancomycin MIC of 4–8 µg/mL,
confirmed by the broth microdilution method, were defined as VISA [21].
Genomic deoxyribonucleic acid (DNA) was extracted using a Wizard genomic DNA
preparation kit (Promega, Madison, WI, USA). According to the manufacturer’s protocol
for bacterial cells, we added lysostaphin at the final concentration of 30 µg/mL in the
lysis buffer and incubated at 37 ◦C for 1 h. MLST, SCCmec typing, and spa typing were
performed in the present study. MLST was carried out by polymerase chain reaction (PCR)
amplification and sequencing of seven housekeeping genes (arc, aroE, glpF, gmk, pta, tpi,
and yqiL) using primer pairs as previously described [22]. The allelic profiles and STs
were assigned by the MLST website (http://saureus.mlst.net/, accessed on 26 October
2020). SCCmec types were determined by the multiplex PCR method [23]. Strains COL,
N315, NCCP13860, and MW2 were included as controls for SCCmec types I, II, III, and IV,
respectively. The spa typing was performed as previously described [24,25]. The spa types
were determined using Ridom SpaServer (http://spa.ridom.de/spatypes.shtml, accessed
on 26 October 2020).
4.4. Vancomycin Consumption and the Vancomycin Minimum Inhibitory Concentrations of
Staphylococcus aureus Isolates
We investigated the amount of vancomycin use and the changes in vancomycin
MICs in S. aureus between March 2020 and August 2020. Data were collected on the
monthly prescription of vancomycin to evaluate the trend in vancomycin use. The DDD
of vancomycin was determined according to the World Health Organization Anatomical
Therapeutic Chemical Classification [26]. The amount of vancomycin consumption is
expressed as the monthly DDD per 1000 PDs. We collected data for vancomycin MICs
of S. aureus isolated from clinical specimens among patients in the hospital. All patients
with S. aureus infection were included in the analysis only once. For patients with isolates
identified repeatedly, only the first isolate was tested.
4.5. Case Definition
The presence of infection with VISA was determined according to the Centers for
Disease Control and Prevention/National Healthcare Safety Network surveillance crite-
ria [27]. Colonisation was defined as the isolation of VISA from clinical samples without
interaction between the host and organism, i.e., in the absence of clinical symptoms or an
immune response.
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